1. Home
  2. GKOS vs CTRE Comparison

GKOS vs CTRE Comparison

Compare GKOS & CTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GKOS
  • CTRE
  • Stock Information
  • Founded
  • GKOS 1998
  • CTRE 2013
  • Country
  • GKOS United States
  • CTRE United States
  • Employees
  • GKOS 995
  • CTRE N/A
  • Industry
  • GKOS Medical/Dental Instruments
  • CTRE Real Estate Investment Trusts
  • Sector
  • GKOS Health Care
  • CTRE Real Estate
  • Exchange
  • GKOS Nasdaq
  • CTRE Nasdaq
  • Market Cap
  • GKOS 5.1B
  • CTRE 4.1B
  • IPO Year
  • GKOS 2015
  • CTRE N/A
  • Fundamental
  • Price
  • GKOS $90.26
  • CTRE $28.75
  • Analyst Decision
  • GKOS Strong Buy
  • CTRE Buy
  • Analyst Count
  • GKOS 13
  • CTRE 7
  • Target Price
  • GKOS $155.00
  • CTRE $30.86
  • AVG Volume (30 Days)
  • GKOS 1.0M
  • CTRE 1.8M
  • Earning Date
  • GKOS 04-30-2025
  • CTRE 05-01-2025
  • Dividend Yield
  • GKOS N/A
  • CTRE 4.66%
  • EPS Growth
  • GKOS N/A
  • CTRE 60.00
  • EPS
  • GKOS N/A
  • CTRE 0.80
  • Revenue
  • GKOS $383,481,000.00
  • CTRE $296,286,000.00
  • Revenue This Year
  • GKOS $27.84
  • CTRE $17.20
  • Revenue Next Year
  • GKOS $27.99
  • CTRE $16.94
  • P/E Ratio
  • GKOS N/A
  • CTRE $35.94
  • Revenue Growth
  • GKOS 21.85
  • CTRE 36.05
  • 52 Week Low
  • GKOS $77.91
  • CTRE $23.26
  • 52 Week High
  • GKOS $163.71
  • CTRE $33.15
  • Technical
  • Relative Strength Index (RSI)
  • GKOS 41.57
  • CTRE 58.99
  • Support Level
  • GKOS $86.16
  • CTRE $27.02
  • Resistance Level
  • GKOS $94.55
  • CTRE $28.08
  • Average True Range (ATR)
  • GKOS 6.54
  • CTRE 0.92
  • MACD
  • GKOS 1.11
  • CTRE 0.01
  • Stochastic Oscillator
  • GKOS 54.51
  • CTRE 79.84

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About CTRE CareTrust REIT Inc.

CareTrust REIT Inc is a self-administered, publicly-traded REIT engaged in the ownership, acquisition, financing, development and leasing of skilled nursing, seniors housing and other healthcare-related properties. The Company has one reportable segment consisting of investments in healthcare-related real estate assets. It generates revenues by leasing healthcare-related properties to healthcare operators in triple-net lease arrangements. The Company generate revenues by leasing healthcare-related properties to healthcare operators in triple-net lease arrangements, under which the tenant is solely responsible for the costs related to the property (including property taxes, insurance, maintenance and repair costs and capital expenditures).

Share on Social Networks: